Patents by Inventor Bruce A. Andrien

Bruce A. Andrien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20240141024
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: July 7, 2023
    Publication date: May 2, 2024
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. SHERIDAN, Paul P. TAMBURINI, Yi WANG
  • Method of quantitating unbound C5 in a sample
    Patent number: 11965884
    Abstract: A method of quantitating free (unbound) human C5 complement protein (C5) from a sample comprising: binding biotinylated anti-C5 capture antibody to strepavidin-coated particles; capturing the free (unbound) C5 in the sample; detecting the captured free C5; and quantitating the captured free C5 using laser-induced fluorescence detection; wherein the method is performed in a Gyros Bioaffy 200 CD in a Gyrolab xPlore or a Gyrolab XP instrument.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: April 23, 2024
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Mark Dysinger, Mark Ma, Bruce A. Andrien
  • RECOMBINANT GLYCOSYLATED ECULIZUMAB AND ECULIZUMAB VARIANTS
    Publication number: 20220324952
    Abstract: The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein having specific glycosylation patterns. The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein made from CHO cells. The present disclosure also relates to methods for the use of these proteins.
    Type: Application
    Filed: April 12, 2022
    Publication date: October 13, 2022
    Inventors: Bruce Andrien, Jeffrey William Hunter, Hunter F. Malanson
  • Anti-C5 antibodies having improved pharmacokinetics
    Patent number: 11434280
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: September 6, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20200157200
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: January 23, 2020
    Publication date: May 21, 2020
    Inventors: Bruce A. ANDRIEN, Jr., Douglas L. SHERIDAN, Paul P. TAMBURINI, Yi WANG
  • Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies
    Patent number: 10584164
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: March 10, 2020
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20190263897
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: January 14, 2019
    Publication date: August 29, 2019
    Inventors: Bruce A. Andrien, JR., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • A METHOD OF QUANTITATING UNBOUND C5 IN A SAMPLE
    Publication number: 20190250157
    Abstract: A method of quantitating free (unbound) human C5 complement protein (C5) from a sample comprising: binding biotinylated anti-C5 capture antibody to strepavidin-coated particles; capturing the free (unbound) C5 in the sample; detecting the captured free C5; and quantitating the captured free C5 using laser-induced fluorescence detection; wherein the method is performed in a Gyros Bioaffy 200 CD in a Gyrolab xPlore or a Gyrolab XP instrument.
    Type: Application
    Filed: October 19, 2017
    Publication date: August 15, 2019
    Inventors: Mark DYSINGER, Mark MA, Bruce A. ANDRIEN
  • Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies
    Patent number: 10227400
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 12, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20180009885
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: September 19, 2017
    Publication date: January 11, 2018
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. SHERIDAN, Paul P. TAMBURINI, Yi WANG
  • Anti-C5 antibodies having improved pharmacokinetics
    Patent number: 9803007
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: October 31, 2017
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20170298123
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 19, 2017
    Inventors: Bruce A. ANDRIEN, JR., Douglas L Sheridan, Paul P. Tamburini, Yi Wang
  • Anti-C5 antibodies having improved pharmacokinetics
    Patent number: 9663574
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: May 30, 2017
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • RECOMBINANT GLYCOSYLATED ECULIZUMAB AND ECULIZUMAB VARIANTS
    Publication number: 20170073399
    Abstract: The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein having specific glycosylation patterns. The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein made from CHO cells. The present disclosure also relates to methods for the use of these proteins.
    Type: Application
    Filed: September 9, 2016
    Publication date: March 16, 2017
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce Andrien, Jeffrey Hunter, Hunter Malanson
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20160251433
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: May 20, 2016
    Publication date: September 1, 2016
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. Sheridan, Paul P. Tamburini
  • Anti-C5 antibodies having improved pharmacokinetics
    Patent number: 9371377
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: June 21, 2016
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini
  • METHOD FOR TREATING A COMPLEMENT MEDIATED DISORDER CAUSED BY AN INFECTIOUS AGENT IN A PATIENT
    Publication number: 20160168237
    Abstract: The present disclosure relates to, inter alia, a method of treating a complement mediated disorder caused by an infectious agents in a patient, comprising administering an effective amount of a C5 inhibitor, such as eculizumab or an eculizumab variant, to the patient.
    Type: Application
    Filed: December 11, 2015
    Publication date: June 16, 2016
    Inventors: Darrell Fontenot, Bridget Puffer, Bruce Andrien, Mittie Doyle, Paul Tamburini, Camille Bedrosian
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20160108115
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: October 27, 2015
    Publication date: April 21, 2016
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. SHERIDAN, Paul P. TAMBURINI
  • Nucleic acids encoding anti-C5 antibodies having improved pharmacokinetics
    Patent number: 9206251
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: December 8, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20150299305
    Abstract: The disclosure provides antibodies that are useful for among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: July 1, 2015
    Publication date: October 22, 2015
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. Sheridan, Paul P. Tamburini